Refine by
Urinary Tract Infections Utis Articles & Analysis
32 news found
Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder characterized by the progressive formation of fluid-filled cysts in the kidneys, often leading to complications, including hypertension, kidney stones, urinary tract infections, and eventually kidney failure. Affecting approximately 12 million people globally, ADPKD currently has no cure, and strategies to ...
Acinetobacter is described by the Centers for Disease Control and Prevention (CDC) as a group of bacteria commonly found in the environment. While there are many types, the most frequent cause of infections in humans is Acinetobacter baumannii. Infections of the blood, urinary tract, and lungs, or in wounds in other parts of the body can all be caused by Acinetobacter baumannii. It can also ...
The Centers for Disease Control and Prevention describe Acinetobacter as a group of bacteria commonly found in the environment in places like soil and water. While there are many types, the most frequent cause of infections in humans is known as Acinetobacter baumannii. Those most at risk of infection according to the CDC include patients in hospitals, especially those who: · are ...
Acinetobacter is described by the Centers for Disease Control and Prevention (CDC) as a group of bacteria commonly found in the environment in places like soil and water. While there are many types, the most frequent cause of infections in humans is known as Acinetobacter baumannii. Infections of the blood, urinary tract and lungs, or in wounds in other parts of the body can all be caused by ...
Zuranolone 50 mg demonstrated a clinically meaningful and statistically significant improvement in depressive symptoms at Day 15, the primary endpoint, and at Days 3, 28, and 45, key secondary endpoints as previously reported Newly presented data offered additional insight into the SKYLARK Study and further demonstrated the rapid improvements in depressive symptoms observed in the clinical ...
LYTGOBI (pronounced “light-GOH-bee”) delivered an objective response rate of 42% and median duration of response of 9.7 months in the primary analysis of the pivotal clinical trial. LYTGOBI covalently binds to FGFR2 and inhibits the signaling pathway. The other approved FGFR inhibitors are reversible ATP-competitive inhibitors. LYTGOBI previously received breakthrough, orphan drug ...
Through its unique bacteriophage discovery, synthetic biology, and manufacturing platform, Locus is developing two innovative categories of biotherapeutics to address significant unmet medical needs: precision CRISPR-enhanced bacteriophage (crPhage®) products to fight deadly infections, including those caused by multi-drug resistant bacteria; and engineered bacteriophage ...
OM Pharma is pleased to announce that Etienne Jornod, its Executive Chairman and co-owner, has been recognised as winner of the Swiss Biotech Success Stories Awards 2022. The awards, bestowed annually by the Swiss Biotech Association, celebrates those who have made important and sustainable contributions to the biotech industry in Switzerland. The Swiss entrepreneur was particularly ...
Before Alexander Fleming discovered penicillin, another more selective antibacterial agent rose to popularity in the early 1900s: bacteriophage. In 1917, microbiologist Felix d’Herelle was tasked with identifying the cause of a dysentery outbreak impacting French troops. From his research, he noticed that Shigella bacteria was the primary culprit of this affliction. He then discovered an ...
REDWOOD CITY, Calif., Feb. 14, 2022 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced positive five-year results from its 181 patient randomized WATER study comparing Aquablation therapy to TURP, the historical standard of care for treating BPH. WATER ...
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to creating novel solutions that treat urothelial and specialty cancers, today announced the first published report of real-world experience utilizing the antegrade approach for Jelmyto® (mitomycin) for pyelocalyceal solution administration in the Journal of Urology online on February 7, 2022. This report provides a stepwise ...
First and only image-guided, heat-free surgical robotic procedure aims to establish a new standard of care for patients with enlarged prostates REDWOOD CITY, Calif., Jan. 18, 2022 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it now has five ...
Millions of people rely on self-catheterization to empty their bladder due to conditions such as urinary bladder retention, spinal cord injury, traumatic brain injury, multiple sclerosis, and more. ...
The award will be presented this evening by the Geneva Chamber of Commerce, Industry and Services (CCIG), the State of Geneva, the Office for the Promotion of Industries and Technologies (OPI) and the Office for the Promotion of Equality and Prevention of Violence (BPEV), during a ceremony at the ‘Bâtiment des Forces Motrices’ in Geneva. The Geneva Economy and Innovation ...
This type of test is typically used for screening and diagnosis of Urinary Tract Infections (UTIs), renal or liver diseases, and diseases that originate in other parts of the body but can be detected through unusually high levels of certain compounds found in urine. ...
ByFluxergy
BioGX, a global provider of molecular diagnostic solutions, announced that the United States Food and Drug Administration has issued Emergency Use Authorization (EUA) for their breakthrough direct sample addition, Xfree™ COVID-19 test. Xfree COVID-19 is a complete test lyophilized in a single tube, for extraction-free, direct sample addition real-time RT-PCR testing. The Xfree COVID-19 ...
Osel, Inc., a company developing live biotherapeutic products (LBPs) for diseases linked to the disruption of the human microbiome, today announced clinical data showing that the company’s LACTIN-V LBP significantly reduced the recurrence of bacterial vaginosis (BV) vs. placebo in a Phase 2b trial. Results were published in the New England Journal of Medicine: “Randomized Trial of ...
Research on biologics, the study of the human genome, and the development of precision diagnostic tools and software have led to new hopes for the development of promising precision medicine. At the same time, the life-sciences commercial sector is still struggling with the challenges of payment structures and value assessment frameworks. As originally conceived, personalized medicine referred ...
ID Genomics, SPC today announced the completion of its first Pre-Submission meeting with the Food and Drug Administration for the CLoNeT E. coli Assay for Urinary Tract Infections (UTIs). “We continue to make great strides in our development plans for the CLoNeT E. coli Assay,” said Linda Zuckerman, Ph.D., President ...
The study, conducted at the clinical lab of a large urgent care facility in Seattle, compared the current standard treatment approach of urinary tract infections (UTIs) with treatment options based on ID Genomics’ technology, which quickly identifies the likely resistance profile of each patient’s ...